Generic Exclusivity Forfeiture Provisions Put FDA In “Hot Seat”
FDA is grappling with how to define triggers for forfeiture of generic exclusivity as it develops regulations to implement changes in Hatch/Waxman created by the Medicare Modernization Act of 2003